July 2023 Announcement

Kova International, Inc. and Biochemical Diagnostics, Inc. (Kova), a leading developer and manufacturer of in vitro urinalysis and toxicology quality control products for clinical laboratories has joined the LGC Clinical Diagnostics family. We’re excited to join LGC Diagnostics as we see this as a perfect fit and complement to their portfolio.

The acquisition grows LGC Clinical Diagnostics’ portfolio in the clinical quality control space, complementing a wide breadth of existing capabilities across biochemistry, serology, molecular, and clinical genomics quality controls and reference materials. LGC Clinical Diagnostics is also a leading provider of biological materials and viral antigens.

Kova includes two locations; Orange County, California, focused on urinalysis quality controls, and Long Island, New York, focused on toxicology quality controls. Kova’s quality controls are used in hospitals, employee wellness programs, forensic testing and medical device manufacturers production and Quality Assurance (QA) programs.

RE: DEVICE REGISTRATION UPDATE:

Effective April 18th 2022, Biochemical Diagnostics has transitioned our EU Representative from Emergo to ADVENA LIMITED.

The following product lines are affected:

DETECTABUSE LIQUID CONTROL URINE

PREGNANCY-SKREEN hCG LIQUID CONTROL

SALIVABUSE LIQUID CONTROL ORAL FLUID

All products previously shipped for sale in any CE Countries are valid under the previous authorized representative and no action needs to be taken.

New orders placed with us after May 5th, will updated labeling to reflect our new Authorized Representative:

ADVENA LIMITED, Tower Business Centre, 2nd Floor, Tower Street, Swatar BKR, 4013 Malta

Please contact us if you have any questions or concerns.